Polypeptide and gene vaccine used for treating alzheimer disease

A technology for Alzheimer's disease and peptide vaccines, applied in vaccines, gene therapy, DNA/RNA vaccination, etc., can solve unreachable problems and achieve the effect of preventing oligomerization

Inactive Publication Date: 2013-12-18
SICHUAN BAILI PHARM CO LTD
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Recent studies have found that Aβ 1-42 The oligomerization of Aβ mainly depends on the amino acid residues located at positions 12-24 and 30-40, so antibodies that can bind to these two peptides can effectively prevent Aβ oligomerization, effectively reduce its neurotoxicity, and achieve slowing down and preventing Or the purpose of reversing the progression of AD, while identifying Aβ 1-42 Antibodies at the N-terminus cannot effectively prevent Aβ oligomerization

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptide and gene vaccine used for treating alzheimer disease
  • Polypeptide and gene vaccine used for treating alzheimer disease
  • Polypeptide and gene vaccine used for treating alzheimer disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] 1. The experimental supplies are as follows:

[0039] Antigen: Aβ 31-42 , Aβ 34-42 , Aβ 37-42 The polypeptide is directly synthesized by Fmoc solid-phase synthesis method, and then coupled with bovine serum albumin (Bovine Serum Albumin, BSA) and succinylated keyhole limpet hemocyanin (KLH) to form a protein-polypeptide complex.

[0040] KLH: Aβ 31-42 , KLH: Aβ 34-42 , KLH: Aβ 37-42 Polypeptide: succinylated keyhole limpet hemocyanin (KLH) coupled to Aβ 31-42 , Aβ 34-42 , Aβ 37-42 peptide.

[0041] BSA: Aβ 31-42 Polypeptide: Bovine Serum Albumin (BSA) coupled to Aβ 31-42 peptide.

[0042] 2. Test animals:

[0043] Immune mice: 10 ten-week-old C57BL / 6J mice or AD model mice APP swe / PS1 ΔE9 (hereinafter referred to as APP / PS1 mice), KLH: Aβ emulsified with Incomplete Freund Adjuvant (Incomplete Freund Adjuvant, IFA) was used at 0, 2, and 4 weeks respectively 31-42 , KLH: Aβ 34-42, KLH: Aβ 37-42 The polypeptide was immunized by intramuscular injection, an...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a polypeptide used for treating alzheimer disease (AD). The amino acid sequence of the polypeptide is Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala. The polypeptide is smart in concept, an Abeta1-42 carboxyl terminal polypeptide Abeta31-42 is taken as an antigen, Th1 immune cell mediated self immunity inflammatory reactions, induced by Abeta16-30, are avoided, an organism can also be effectively induced to produce an antibody for identifying an Abeta1-42 carboxyl terminal, Abeta oligomerization is prevented, neurovirulence of an Abeta oligomer is effectively inhibited, and the aim of treating AD is achieved.

Description

technical field [0001] The invention relates to a polypeptide and a gene vaccine, in particular to a polypeptide and a gene vaccine for treating Alzheimer's disease. Background technique [0002] Alzheimer's disease (Alzheimer's Disease, AD) is the so-called senile dementia, which is a progressive and fatal neurodegenerative disease. And there are various neuropsychiatric symptoms and behavioral disturbances. [0003] AD mostly occurs in the elderly, with latent onset, slow and irreversible course, and clinically, mental impairment is the main symptom. The pathological changes are mainly diffuse atrophy of the cortex, widening of the sulci, enlarged ventricles, a large reduction of neurons, and β-amyloid (Amyloid β, Aβ) plaques, neurofibrillary tangles and other lesions, choline acetylase And the content of acetylcholine was significantly reduced. Among them, β-amyloid plaques and neurofibrillary tangles are the two core pathological features of AD, and their core compone...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/08C07K7/06A61K48/00A61K39/00A61P25/28
CPCA61K39/0007A61K2039/53A61K2039/55505A61K2039/55566A61K2039/55577A61K2039/6037A61K2039/6043A61K2039/6081A61P25/28C07K7/06C07K7/08
Inventor 朱义
Owner SICHUAN BAILI PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap